CN1259523A - Immuno active polypeptide for treating psoriasis and its prepn. method - Google Patents
Immuno active polypeptide for treating psoriasis and its prepn. method Download PDFInfo
- Publication number
- CN1259523A CN1259523A CN99118944A CN99118944A CN1259523A CN 1259523 A CN1259523 A CN 1259523A CN 99118944 A CN99118944 A CN 99118944A CN 99118944 A CN99118944 A CN 99118944A CN 1259523 A CN1259523 A CN 1259523A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- freeze
- prepn
- spleen
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A polypeptide prepn. is prepn. through inject antigen, take material, break membrane and centrifuge, extract, remove bacteria, freeze drying to obtain the product, its molecular weight is smaller than 10000 polypeptide, maximum absorption peak value of ultraviolet ray is 252 nm, 260 nm/280 nm greather than 2. Clinical experiments showed that it is apparent in curing effect against psoriasis. The present invention is natural immune active substance produced in organisms, so it has no side effect after use, and is safe and reliable.
Description
The present invention relates to a kind of pharmaceutical preparation and preparation method thereof, relate in particular to a kind of immuno active polypeptide pharmaceutical preparation and preparation method thereof, to treat psoriatic safely and effectively.
At present, the relevant expert thinks that onset of psoriasis is subjected to multifactor control, removes foreign genetic element, infect (bacterium, virus), stress (direct stimulation, wound), immune dysfunction etc. all is risk factor.
Because etiology unknown does not still have specific short so far, the common chemical preparation has toxicity in various degree more, though Chinese medicine toxicity is less, the course of treatment is longer.Therapy at present commonly used can not solve the recurrence problem, thus be badly in need of development safety, effectively, can prevent the medicine that recurs.
The objective of the invention is provides a kind of significant curative effect that has for clinical, and can suppress recurrence, and the medicine that has no side effect again is to treat psoriatic safely and effectively.
The present invention is achieved in that
We contain hepatitis B virus DNA and expression product thereof experimental studies have found that for many years in the sick damage of the psoriatic place tissue.The present invention is an antigen with antigen compositions such as hepatitis B virus composition and pathogenic suis, the desirable sheep of immune animal, pig etc., behind skin test proof animal Yinchuan City cell sensitization, aseptic technique, draw materials: get its spleen, lymphoglandula rupture of membranes, afterwards through freeze thawing (25 ℃～-40 ℃) or ultrasonication.Centrifugal again (4500 rev/mins) remove slag.Through MW50000, the ultrafiltration of MW10000 filter, degerming pours into 2ml peace bottle (in add 4%W/V N.F,USP MANNITOL), makes every to contain polypeptide 1mg, and-30 ℃～-40 ℃ freeze-drying are sealed.Perhaps pour into freeze-drying in the plate, collect dry powder and incapsulate, the contains polypeptide 3mg.
Above after quality inspection and proof test are qualified, for clinical use.
Operating process is as follows:
Injections of antigens (animal is used sheep, pig etc.)
↓
(spleen, the lymphoglandula) aseptic technique of drawing materials
↓
Rupture of membranes, centrifugal (through freeze thawing, ultrasonication, 4500 rev/mins)
↓
Extract (ultrafiltration of crossing MW10000)
↓
Degerming (through degerming filter membrane etc. or funnel)
↓
Freeze-drying (30 ℃ 48-72 hour)
Finished product are that molecular weight is less than 10000 polypeptide, and the ultraviolet maximum absorption peak is 252nm, 260nm/280nm＞2.
Methods of treatment of the present invention: each 1 of injection (containing 1mg/ props up), once a day, after the onset intramuscular injection in 2-3 days once, each 2 of oral preparation (30mg/ grain), children reduce by half, and once a day, cut down according to the circumstance after the onset.
Observe inpatient's 27 examples through The Fourth Military Medical University's Xijing hospital dermatology department, wherein healing, produce effects, effective routine number are respectively 11 examples, 9 examples, 5 examples, respectively account for 41%, 33%, 18%, and total effective 25 examples account for 93%.Three batches of totally 146 examples are observed by air force general hospital Dermatology Department, and its recovery from illness, produce effects and effective routine number are respectively 39 examples, 45 example and 50 examples, respectively account for 27%, 31% and 34%, and total effective rate is 92%.More than two observation group of unit curative effects all be higher than control group (the ox spleen transfer factor that injection Beijing first biochemical-pharmaceutical factory is produced) all there were significant differences in P＜0.01.
This therapy is rapid-action, improvement 3-7 days, produce effects 9-13 days, cures 15-26 days.
The director Cai Ruikang chief physician of air force general hospital Dermatology Department lasts 5 years through hundreds of examples being in hospital and outpatient service psoriatic patient's treatment is observed and thought: this method curative effect is obvious, and is to chronic, that show effect repeatedly and particularly remarkable with immunologic function patient's curative effect on the low side.To delaying recurrence time, alleviating severity extent all has unusual effect, for reducing or avoiding recurrence that the definite effective therapy is provided.This preparation is the natural immunity active substance that produces in the organism, has no side effect after the use, and this law is safe and reliable new therapy.
Claims (2)
1. preparation method who controls psoriatic immuno active polypeptide is characterized in that:
1. injections of antigens: with hepatitis B virus, the suis composition that causes a disease is antigen, and the desirable sheep of immune animal, pig carry out subcutaneous injection;
2. draw materials: behind skin test proof animal immune cell sensitization, aseptic technique draw materials its spleen, lymphoglandula;
3. rupture of membranes, centrifugal: to spleen, lymphoglandula rupture of membranes, in-25 ℃～-40 ℃ freeze thawing or ultrasonication again with 4500 rev/mins of centrifugal removing slag;
4. extract: will go up material and cross MW50000, the ultrafiltration of MW10000 filter;
5. degerming: add 4%W/V N.F,USP MANNITOL through degerming filter membrane or funnel and make every to contain polypeptide 1mg or every and contain polypeptide 3mg;
6. freeze-drying:, freeze-drying in 48-72 hour, seal, pack at 30 ℃.
2. according to the prepared polypeptide of claim 1, it is characterized in that: described polypeptide is that molecular weight is less than 10000 polypeptide, and the ultraviolet maximum absorption peak is 252nm, 260nm/280nm＞2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99118944A CN1259523A (en) | 1999-08-31 | 1999-08-31 | Immuno active polypeptide for treating psoriasis and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99118944A CN1259523A (en) | 1999-08-31 | 1999-08-31 | Immuno active polypeptide for treating psoriasis and its prepn. method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1259523A true CN1259523A (en) | 2000-07-12 |
Family
ID=5280604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99118944A Pending CN1259523A (en) | 1999-08-31 | 1999-08-31 | Immuno active polypeptide for treating psoriasis and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1259523A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721807A (en) * | 2015-04-13 | 2015-06-24 | 刘冬明 | Oral liquid for treating psoriasis |
-
1999
- 1999-08-31 CN CN99118944A patent/CN1259523A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721807A (en) * | 2015-04-13 | 2015-06-24 | 刘冬明 | Oral liquid for treating psoriasis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scheller et al. | The ability of ethanol extract of propolis to stimulate plaque formation in immunized mouse spleen cells | |
| EP2156841A1 (en) | Conditioned blood compound and method for its manufacture | |
| CN102056619A (en) | Methods of generating and using procollagen | |
| Szpunar | Laryngeal papillomatosis | |
| CN106075436B (en) | An oral preparation containing no antibiotic for resisting helicobacter pylori | |
| US20220152129A1 (en) | External composition for wound healing containing lactobacillus fermentation product and method for promoting wound healing using the same | |
| Jadhav et al. | Antivenin production in India | |
| CN1259523A (en) | Immuno active polypeptide for treating psoriasis and its prepn. method | |
| EP0234405B1 (en) | Use of an immunoglobulin-containing composition in the prophylaxis and therapy of AIDS of human | |
| KR101407611B1 (en) | Dioscoreae Rhizoma comprising the manufacture of a medicament for the treatment of facial nerve paralysis, and the extract beongbeop | |
| CN103463618B (en) | Application of recombinant ganoderma lucidum immunoregulatory protein in preparing drug for treating focal cerebral ischemia | |
| Jong et al. | Praziquantel for the treatment of Clonorchis/Opisthorchis infections: report of a double-blind, placebo-controlled trial | |
| CN116196333A (en) | THC-loaded stem cell source exosome skin homeostasis agent and preparation method and application thereof | |
| CN112691114B (en) | Application of momordica polysaccharide in preparation of medicine for treating ulcerative colitis and pharmaceutical preparation of momordica polysaccharide | |
| EP0265548B1 (en) | Process for the preparation of germ-killed or of attenuated virulence substances, and their use | |
| CN111978394B (en) | Preparation method of polyclonal preparation for COVID-19 patient specific immunotherapy | |
| CN114470007A (en) | Wound external composition containing lactic acid bacteria fermentation product and use thereof | |
| KR100341172B1 (en) | Remedy for axillary osmidrosis containing adrenocorticosteriodal preparation | |
| WO2004101621A1 (en) | A SPECIFIC IMMUNOGLOBULIN (Ig) Y AGAINST SEVERVE ACUTE RTESPIRATORY SYNDROME (SARS) AND A PREPARING METHOD THEREOF AND COMBINATION PREPARATIOS CONTAINING IT | |
| EP0889053B1 (en) | BK-RiV preparations for teatment of proliferative cellular disorders | |
| JPH09315998A (en) | Preventing and treating agent for allergy to cedar pollen | |
| CN115444934A (en) | Composition for preventing and treating HPV (human papilloma virus), and preparation method and application thereof | |
| DE3485773T2 (en) | MACROMOLECULES EXTRACTED FROM CULTIVATED MESENCHYM CELLS FOR THE TREATMENT OF DEGENERATIVE DISEASES. | |
| CN100593418C (en) | Spray for treating burn | |
| RU2116082C1 (en) | Method of preparing gamma-globulin for treatment of horses with epizootic lymphangoitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |